SMMT - 24/7 Market News- Summit Therapeutics Reported Positive Phase III Clinical Trial Data

2024-05-30 15:34:05 ET

DENVER, Colo., May 30, 2024 ( 247marketnews.com )- Summit Therapeutics Inc. (NASDAQ: SMMT ) reported that the HARMONi-2, or AK112-303, Phase III clinical trial met its primary endpoint of progression-free survival (PFS). HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expression (PD-L1 TPS > 1%).

MoBot alerted Summit Therapeutics yesterday at $2.886. Please sign up for free MoBot alerts and view Mobot’s real time data at www.247marketnews.com .

“HARMONi-2 clearly demonstrates that ivonescimab is the next generation in PD-1 directed immunotherapy, and its potential to make a significant difference in the lives of patients with lung cancer and prospectively other tumors,” said Dr. Maky Zanganeh, Chief Executive Officer and President of Summit. “We want to congratulate our partners at Akeso for this incredible result and their work to advance the patient-friendly standards of care today and well into the future. This result validates Team Summit’s present-time intention to execute a development plan worthy of ivonescimab’s emergent potential – including clinical trials in both NSCLC and other solid tumors where ivonescimab can improve upon existing standards of care.”

“This is an historic moment for ivonescimab, Team Summit, our partners at Akeso, and most importantly, we believe this is the beginning of a paradigm change for treatment options for patients living with cancer,” commented Summit’s Chairman and Chief Executive Officer, Robert W. Duggan. “We are incredibly proud of our partnership with Akeso and their accomplishment with the HARMONi-2 trial.”

The post 24/7 Market News- Summit Therapeutics Reported Positive Phase III Clinical Trial Data appeared first on 24/7 MarketNews .

For further details see: